CD38 is also expressed on normal white blood cells, although at lower levels than on MM cells.1 Daratumumab and isatuximab can trigger neutropenia or thrombocytopenia, which often requires mAb dose reduction or a halt of the treatment. The gene discussed is CD38; the disease is Miyoshi myopathy.